Cargando…
Case report: Daratumumab treatment in pre-transplant alloimmunization and severe hemolytic anemia
Daratumumab, a CD38 monoclonal antibody that has been FDA-approved to treat multiple myeloma, has acquired popularity and is used off-label for both auto- and alloantibody mediated disorders, particularly in refractory/resistant circumstances. Much of the published data for its use in pediatric bloo...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744936/ https://www.ncbi.nlm.nih.gov/pubmed/36524117 http://dx.doi.org/10.3389/fimmu.2022.1055473 |